Comments
Pharma major Dr Reddy's Laboratories Ltd has entered into an agreement with the US-based Oceana Therapeutics to sell and distribute its drug Deflux in India. Deflux is indicated for the treatment of vesicoureteral reflux (VUR – a malformation of urinary bladder) in children.
“By leveraging the therapeutic value of Deflux with the strengths of Dr Reddy's resources, we foresee a significant opportunity to serve a wider patient population in India with an important treatment for VUR,” Mr Gregory Stokes, Executive Vice-President, Business Development, Oceana, said in a release hosted on company's Web site.
The global sales of Deflux in 2008 were at about $30 million, the New Jersey-based company said. When contacted, a functionary of Dr Reddy's told Business Line that though Deflux was not a big product, it would help the Hyderabad-based company increase its offerings in the segment. The financial aspects of the agreement were not disclosed.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.